PMID- 23093894
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121025
LR  - 20211021
IS  - 1174-2704 (Electronic)
IS  - 1174-2704 (Linking)
VI  - 5
IP  - 1
DP  - 2012 Jul
TI  - The burden of adverse events during treatment of drug-resistant tuberculosis in 
      Namibia.
PG  - 6-13
AB  - OBJECTIVE: Namibia faces a dual burden of HIV/AIDS and tuberculosis (TB). In 
      2010, HIV prevalence was 18.8%, the TB case notification rate was 634 cases per 
      100,000 population and the TB/HIV co-infection rate was 58%. There were 372 cases 
      of drug-resistant TB (DR-TB) in 2009. The objective of this study was to assess 
      the prevalence, profile and outcome of adverse events (AEs) associated with 
      treatment of DR-TB and to explore possible influences of HIV disease on the 
      occurrence of adverse events. METHODS: This was a cross-sectional descriptive 
      study. After ethical approval, data were collected from treatment records of all 
      patients treated for DR-TB at the study facility between January 2008 and 
      February 2010 using a structured data collection form. RESULTS: A total of 141 
      adverse events of varying severity were experienced in 90% (53/59) of 
      patients.The TB/HIV co-infection rate was 53% (n=31). The prevalence of 
      gastrointestinal tract adverse events (abdominal pains, constipation, diarrhea, 
      nausea and vomiting) was 64%, tinnitus 45%, joint pain 28%and decreased hearing 
      25%. Abdominal pains, rash, nausea, decreased hearing and joint pain were more 
      common in HIV infected than in HIV uninfected patients. CONCLUSIONS: Adverse 
      events of varying severity are common during treatment of DR-TB, particularly in 
      the intensive phase of therapy. Some adverse events were more prevalent in DR-TB 
      patients co-infected with HIV. The study concludes that the characteristics and 
      risk factors of serious adverse events should be further examined.
FAU - Sagwa, Evans
AU  - Sagwa E
AD  - School of Public Health, University of the Western Cape, Cape Town, South Africa 
      ; Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology 
      and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands ; 
      Management Sciences for Health, Strengthening Pharmaceutical Systems Program, 
      Namibia.
FAU - Mantel-Teeuwisse, Aukje Kaija
AU  - Mantel-Teeuwisse AK
FAU - Ruswa, Nunurai
AU  - Ruswa N
FAU - Musasa, Jean Paul
AU  - Musasa JP
FAU - Pal, Shanthi
AU  - Pal S
FAU - Dhliwayo, Panganai
AU  - Dhliwayo P
FAU - van Wyk, Brian
AU  - van Wyk B
LA  - eng
PT  - Journal Article
DEP - 20120723
PL  - New Zealand
TA  - South Med Rev
JT  - Southern med review
JID - 101571840
PMC - PMC3471190
OTO - NOTNLM
OT  - Namibia
OT  - adverse events
OT  - drug resistance
OT  - second-line drugs
OT  - tuberculosis
EDAT- 2012/10/25 06:00
MHDA- 2012/10/25 06:01
PMCR- 2012/07/01
CRDT- 2012/10/25 06:00
PHST- 2012/10/25 06:00 [entrez]
PHST- 2012/10/25 06:00 [pubmed]
PHST- 2012/10/25 06:01 [medline]
PHST- 2012/07/01 00:00 [pmc-release]
PST - ppublish
SO  - South Med Rev. 2012 Jul;5(1):6-13. Epub 2012 Jul 23.